{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T01:26:09Z","timestamp":1760318769416,"version":"3.35.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2008,11,11]],"date-time":"2008-11-11T00:00:00Z","timestamp":1226361600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1007\/s00280-008-0862-z","type":"journal-article","created":{"date-parts":[[2008,11,10]],"date-time":"2008-11-10T17:31:49Z","timestamp":1226338309000},"page":"253-261","source":"Crossref","is-referenced-by-count":8,"title":["Enhancement of the in vivo antitumor activity of clofarabine by 1-\u03b2-d-[4-thio-arabinofuranosyl]-cytosine"],"prefix":"10.1007","volume":"64","author":[{"given":"William B.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sue C.","family":"Shaddix","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen S.","family":"Gilbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney V.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William R.","family":"Waud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,11,11]]},"reference":[{"key":"862_CR1","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/nrd2055","volume":"5","author":"PL Bonate","year":"2006","unstructured":"Bonate PL, Arthaud L, Cantrell WR Jr, Stephenson K, Secrist JA III, Weitman S (2006) Discovery and development of clofarabine: a nucleoside analogue for treating cancer. Nat Rev Drug Discov 5:855\u2013863","journal-title":"Nat Rev Drug Discov"},{"key":"862_CR2","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1002\/cncr.21005","volume":"103","author":"S Faderl","year":"2005","unstructured":"Faderl S, Gandhi V, Keating MJ, Jeha S, Plunkett W, Kantarjian HM (2005) The role of clofarabine in hematologic and solid malignancies\u2014development of a next-generation nucleoside analog. Cancer 103:1985\u20131995","journal-title":"Cancer"},{"key":"862_CR3","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1080\/10428190701545644","volume":"48","author":"HM Kantarjian","year":"2007","unstructured":"Kantarjian HM, Jeha S, Gandhi V, Wess M, Faderl S (2007) Clofarabine: past, present, and future. Leuk Lymphoma 48:1922\u20131930","journal-title":"Leuk Lymphoma"},{"key":"862_CR4","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/s00280-004-0906-y","volume":"55","author":"T Cooper","year":"2005","unstructured":"Cooper T, Ayres M, Nowak B, Gandhi V (2005) Biochemical modulation of cytarabine triphosphate by clofarabine. Cancer Chemother Pharmacol 55:361\u2013368","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR5","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2004-05-1933","volume":"105","author":"S Faderl","year":"2005","unstructured":"Faderl S, Gandhi V, O\u2019Brien S, Bonate P, Cortes J, Estey E, Beran M, Wierda W, Garcia-Manero G, Ferrajoli A, Estrov Z, Giles FJ, Du M, Kwari M, Keating M, Plunkett W, Kantarjian H (2005) Results of a phase 1\u20132 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias. Blood 105:940\u2013947","journal-title":"Blood"},{"key":"862_CR6","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1182\/blood-2005-08-3294","volume":"108","author":"S Faderl","year":"2006","unstructured":"Faderl S, Verstovsek S, Cortes J, Ravandi F, Beran M, Garcia-Manero G, Ferrajoli A, Estrov Z, O\u2019Brien S, Koller C, Giles FJ, Wierda W, Kwari M, Kantarjian HM (2006) Clofarabine and cytarabine combination as induction therapy for acute myeloid leukemia (AML) in patients 50\u00a0years of age or older. Blood 108:45\u201351","journal-title":"Blood"},{"key":"862_CR7","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000118664","volume":"54","author":"P Gidwani","year":"2008","unstructured":"Gidwani P, Ramesh KH, Liu Y, Kolb EA (2008) The combination of clofarabine and cytarabine in pediatric relapsed acute lymphoblastic leukemia: a case report. Chemotherapy 54:120\u2013124","journal-title":"Chemotherapy"},{"key":"862_CR8","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1080\/15257770008033012","volume":"19","author":"KN Tiwari","year":"2000","unstructured":"Tiwari KN, Shortnacy-Fowler AT, Cappellacci L, Parker WB, Waud WR, Montgomery JA, Secrist JA III (2000) Synthesis of 4\u2032-thio-\u03b2-d-arabinofuranosyl-cytosine (4\u2032-thio-ara-C) and comparison of its anticancer activity with that of ara-C. Nucleosides Nucleotides Nucleic Acids 19:329\u2013340","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"862_CR9","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s00280-003-0589-9","volume":"51","author":"WR Waud","year":"2003","unstructured":"Waud WR, Gilbert KS, Shepherd RV, Montgomery JA, Secrit JA III (2003) Preclinical antitumor activity of 4\u2032-thio-beta-d-arabinofuranosylcytosine (4\u2032-thio-ara-C). Cancer Chemother Pharmacol 51:422\u2013426","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR10","first-page":"714","volume":"45","author":"WR Waud","year":"2004","unstructured":"Waud WR, Shepherd RV, Gilbert KS, Tiwari KN, Secrist JA III (2004) Precinical antitumor activity of 4\u2032-thio-\u03b2-d-arabinofuranosylcytosine (4\u2032-thio-ara-C, OSI-7836) in human leukemia and lymphoma xenograft models. Proc Am Assoc Cancer Res 45:714","journal-title":"Proc Am Assoc Cancer Res"},{"key":"862_CR11","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1016\/S0006-2952(00)00520-7","volume":"60","author":"WB Parker","year":"2000","unstructured":"Parker WB, Shaddix SC, Rose LM, Waud WR, Shewach DS, Tiwari KN, Secrist JA III (2000) Metabolism of 4\u2032-thio-\u03b2-d-arabinofuranosylcytosine in CEM cells. Biochem Pharmacol 60:1925\u20131932","journal-title":"Biochem Pharmacol"},{"key":"862_CR12","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00280-004-0844-8","volume":"55","author":"F Richardson","year":"2005","unstructured":"Richardson F, Black C, Richardson K, Franks A, Wells E, Karimi S, Sennello G, Hart K, Meyer D, Emerson D, Brown E, LeRay J, Nilsson C, Tomkinson B, Bendele R (2005) Incorporation of OSI-7836 into DNA of Calu-6 and H460 xenograft tumors. Cancer Chemother Pharmacol 55:213\u2013221","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR13","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1124\/mol.105.021543","volume":"70","author":"ML Clarke","year":"2006","unstructured":"Clarke ML, Damaraju VL, Zhang J, Mowles D, Tackaberry T, Lang T, Smith KM, Young JD, Tomkinson B, Cass CE (2006) The role of human nucleoside transporters in cellular uptake of 4\u2032-thio-beta-d-arabinofuranosylcytosine and beta-d-arabinosylcytosine. Mol Pharmacol 70:303\u2013310","journal-title":"Mol Pharmacol"},{"key":"862_CR14","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1016\/j.bcp.2004.07.042","volume":"68","author":"KA Richardson","year":"2004","unstructured":"Richardson KA, Vega TP, Richardson FC, Moore CL, Rohloff JC, Tomkinson B, Bendele RA, Kuchta RD (2004) Polymerization of the triphosphates of AraC, 2\u2032,2\u2032-difluorodeoxycytidine (dFdC) and OSI-7836 (T-araC) by human DNA polymerase alpha and DNA primase. Biochem Pharmacol 68:2337\u20132346","journal-title":"Biochem Pharmacol"},{"key":"862_CR15","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1124\/jpet.102.045435","volume":"304","author":"H Someya","year":"2003","unstructured":"Someya H, Shaddix SC, Tiwari KN, Secrist JA III, Parker WB (2003) Phosphorylation of 4\u2032-thio-\u03b2-d-arabinofuranosylcytosine and its analogs by human deoxycytidine kinase. J Pharmacol Exp Ther 304:1314\u20131322","journal-title":"J Pharmacol Exp Ther"},{"key":"862_CR16","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s00280-005-0126-0","volume":"57","author":"H Someya","year":"2006","unstructured":"Someya H, Waud WR, Parker WB (2006) Long intracellular retention of 4\u2032-thio-arabinofuranosylcytosine 5\u2032-triphosphate as a critical factor for the anti-solid tumor activity of 4\u2032-thio-arabinofuranosylcytosine. Cancer Chemother Pharmacol 57:772\u2013780","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR17","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/1535-7163.MCT-05-0409","volume":"5","author":"JV Thottassery","year":"2006","unstructured":"Thottassery JV, Westbrook L, Someya H, Parker WB (2006) c-Abl-independent p73 stabilization during gemcitabine- or 4\u2032-thio-beta-d-arabinofuranosylcytosine-induced apoptosis in wild-type and p53-null colorectal cancer cells. Mol Cancer Ther 5:400\u2013410","journal-title":"Mol Cancer Ther"},{"key":"862_CR18","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s00280-006-0201-1","volume":"58","author":"G Goss","year":"2006","unstructured":"Goss G, Siu LL, Gauthier I, Chen EX, Oza AM, Goel R, Maroun J, Powers J, Walsh W, Maclean M, Drolet DW, Rusk J, Seymour LK, Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group (2006) A phase I, first in man study of OSI-7836 in patients with advanced refractory solid tumors: IND.147, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group. Cancer Chemother Pharmacol 58:703\u2013710","journal-title":"Cancer Chemother Pharmacol"},{"key":"862_CR19","doi-asserted-by":"crossref","first-page":"2841","DOI":"10.1158\/1078-0432.CCR-05-1932","volume":"12","author":"CP Lee","year":"2006","unstructured":"Lee CP, de Jonge MJ, O\u2019Donnell AE, Schothorst KL, Hanwell J, Chick JB, Brooimans RA, Adams LM, Drolet DW, de Bono JS, Kaye SB, Judson IR, Verweij J (2006) A phase I study of a new nucleoside analogue, OSI-7836, using two administration schedules in patients with advanced solid malignancies. Clin Cancer Res 12:2841\u20132848","journal-title":"Clin Cancer Res"},{"key":"862_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000421255","volume":"42","author":"DJ Dykes","year":"1992","unstructured":"Dykes DJ, Abbott BJ, Mayo JG, Harrison SD Jr, Laster WR, Simpson-Herren L, Griswold DP Jr (1992) Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. Contrib Oncol Basel Karger 42:1\u201322","journal-title":"Contrib Oncol Basel Karger"},{"key":"862_CR21","first-page":"6335","volume":"9","author":"V Gandhi","year":"2003","unstructured":"Gandhi V, Kantarjian H, Faderl S, Bonate P, Du M, Ayres M, Rios MB, Keating MJ, Plunkett W (2003) Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias. Clin Cancer Res 9:6335\u20136342","journal-title":"Clin Cancer Res"},{"key":"862_CR22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1080\/15257770008033020","volume":"19","author":"WR Waud","year":"2000","unstructured":"Waud WR, Schmid SM, Montgomery JA, Secrist JA III (2000) Preclinical antitumor activity of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) adenine (Cl\u2013F-ara-A). Nucleosides Nucleotides Nucleic Acids 19:447\u2013460","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"862_CR23","first-page":"2386","volume":"51","author":"WB Parker","year":"1991","unstructured":"Parker WB, Shaddix SC, Chang CH, White EL, Rose LM, Brockman RW, Shortnancy AT, Montgomery JA, Secrist JA III, Bennett LL Jr (1991) Effects of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-d-arabinofuranosyl) adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5-triphosphate. Cancer Res 51:2386\u20132394","journal-title":"Cancer Res"},{"key":"862_CR24","first-page":"2847","volume":"55","author":"C Xie","year":"1995","unstructured":"Xie C, Plunkett W (1995) Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl)-adenine in human lymphoblastoid cells. Cancer Res 55:2847\u20132852","journal-title":"Cancer Res"},{"key":"862_CR25","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0026-895X(24)12176-1","volume":"55","author":"WB Parker","year":"1999","unstructured":"Parker WB, Shaddix SC, Rose LM, Shewach DS, Hertel LW, Secrist JA III, Montgomery JA, Bennett LL Jr (1999) Comparison of the mechanism of cytotoxicity of 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-d-arabinofuranosyl) adenine, 2-chloro-9-(2-deoxy-2-fluoro-\u03b2-d-ribofuranosyl) adenine, and 2-chloro-9-(2-deoxy-2,2-difluoro-\u03b2-d-ribofuranosyl) adenine in CEM cells. Mol Pharmacol 55:515\u2013520","journal-title":"Mol Pharmacol"},{"key":"862_CR26","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1016\/S0959-8049(99)00223-3","volume":"35","author":"T Spasokoukotskaja","year":"1999","unstructured":"Spasokoukotskaja T, Sasv\u00e1ri-Sz\u00e9kely M, Keszler G, Albertioni F, Eriksson S, Staub M (1999) Treatment of normal and malignant cells with nucleoside analogues and etoposide enhances deoxycytidine kinase activity. Eur J Cancer 35:1862\u20131867","journal-title":"Eur J Cancer"},{"key":"862_CR27","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0006-2952(00)00534-7","volume":"61","author":"Z Csap\u00f3","year":"2001","unstructured":"Csap\u00f3 Z, Sasv\u00e1ri-Sz\u00e9kely M, Spasokoukotskaja T, Talianidis I, Eriksson S, Staub M (2001) Activation of deoxycytidine kinase by inhibition of DNA synthesis in human lymphocytes. Biochem Pharmacol 61:191\u2013197","journal-title":"Biochem Pharmacol"},{"key":"862_CR28","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1080\/15257770600894345","volume":"25","author":"G Keszler","year":"2006","unstructured":"Keszler G, Spasokoukotskaja T, Sasv\u00e1ri-Sz\u00e9kely M, Eriksson S, Staub M (2006) Deoxycytidine kinase is reversibly phosphorylated in normal human lymphocytes. Nucleosides Nucleotides Nucleic Acids 25:1147\u20131151","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"862_CR29","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1007\/BF00686505","volume":"33","author":"M Qian","year":"1994","unstructured":"Qian M, Wang X, Shanmuganathan K, Chu CK, Gallo JM (1994) Pharmacokinetics of the anticancer agent 2-chloro-9-(2-deoxy-2-fluoro-beta-d-arabinofuranosyl) adenine in rats. Cancer Chemother Pharmacol 33:484\u2013488","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0862-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-008-0862-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-008-0862-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T16:28:50Z","timestamp":1738513730000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-008-0862-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11,11]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["862"],"URL":"https:\/\/doi.org\/10.1007\/s00280-008-0862-z","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"type":"print","value":"0344-5704"},{"type":"electronic","value":"1432-0843"}],"subject":[],"published":{"date-parts":[[2008,11,11]]}}}